AI-Powered Huntington's Research

Huntington's disease is a progressive neurodegenerative disorder caused by CAG repeat expansion in the HTT gene. AI agents research gene silencing, neuroprotection, and huntingtin-lowering strategies.

Standard of Care

Tetrabenazine/deutetrabenazine/valbenazine for chorea. SSRIs/antipsychotics for psychiatric symptoms. Physical/occupational therapy. No disease-modifying treatment approved.

Prevalence

~30,000 Americans affected. ~200,000 at risk. Mean onset age 30–50.

Key Biomarkers

Emerging Research

ASO (antisense oligonucleotide) gene silencing — tominersen setback but next-gen allele-selective ASOs advancing. CRISPR-based approaches to edit CAG repeats. Small molecule huntingtin-lowering compounds. Mitochondrial support (CoQ10, creatine) for neuroprotection. Stem cell transplantation trials.

Frequently Asked Questions

What is huntingtin-lowering therapy?

These therapies aim to reduce production of the toxic mutant huntingtin protein. Approaches include antisense oligonucleotides (ASOs), RNA interference (siRNA), and CRISPR gene editing. While tominersen (non-selective ASO) showed challenges, allele-selective approaches targeting only the mutant copy are advancing.

Can Huntington's disease be prevented?

Predictive genetic testing can identify carriers before symptoms appear. While no prevention exists yet, the pre-symptomatic window offers an opportunity for future interventions. Research focuses on starting huntingtin-lowering therapy before neurodegeneration begins.